

Industry Discovery & Development Partnership (IDDP) Program Overview


Research

Partnerships/Business Development



Breakthrough T1D™

Formerly JDRF



Purpose and Aims

The purpose of the IDDP Program is to provide support to for-profit entities for research programs that are closely aligned with Breakthrough T1D's priority areas.

The program aims to:

- Accelerate the development and commercialization of therapeutics and devices for the treatment, cure, and prevention of T1D and its complications
- Foster long-term collaborative relationships among Breakthrough T1D, industry partners, and the T1D community



Eligibility

- Biotech, pharma, and other for-profit entities, either public or private
- Projects may include company partnerships with academic investigators, contract research organizations (CROs), or other entities.
- Matching resources (or matched funds): Applicants will be required to commit funding to the project in an amount *equal to or greater than* the amount requested for the duration of the Breakthrough T1D funding.



Strategic Alignment

The applicant must propose a project focused on the discovery and/or development of therapeutics and/or devices to cure, treat and/or prevent T1D that is aligned with [Breakthrough T1D's Research Strategy](#).

The proposal must include the following:

- Description of the company's pipeline product(s) for T1D and its complications
- Development path toward potential commercialization, with regulatory considerations included as appropriate



Application and Review Process


Pre-LOI: Eligibility and Alignment Assessments

Applicants must do the following *prior to* submitting a letter of intent (LOI):

- Contact Breakthrough T1D staff
- Provide a non-confidential pitch deck and/or summary of the proposed research project

Projects must be focused on a specific research project that is well-aligned with [Breakthrough T1D's Research Strategy](#).

Applicant may choose to initiate a **non-disclosure agreement (NDA)**.




Letter of Intent (LOI)

A **Letter of Intent (LOI)** is:

- By invitation
- Submitted through Breakthrough T1D's grant management system, [RMS360](#).
- Shared with the venture philanthropy team at the [T1D Fund](#).
- Applicant will be asked to provide a budget, company information, including financials.

If the LOI review is positive, the applicant will be invited to submit a **full application**.

**NOTE: All proposals submitted in RMS are covered by confidentiality. All volunteers, staff, etc., including the Fund, are covered by a confidentiality policy.*



Full Proposal, Term Sheet, and Agreement

Full proposal will undergo **external peer review** and a rebuttal period.

The applicant

- Will work with Breakthrough T1D throughout the submission process.
- Will be provided with a **non-binding term sheet** after submission of the full application (proposal).

Contingent upon agreement of the high-level terms in the term sheet, Breakthrough T1D will issue an **agreement** for review.

A **finalized definitive agreement** is required for Breakthrough T1D to bring the IDDP funding opportunity for final approval.

IDDP Projects are administered and governed by an agreement negotiated between the parties (“Company” and Breakthrough T1D). All aspects of the relationship are described in the agreement, including but not limited to the following:

1. Research scope, study design, key personnel, critical suppliers/supplies, etc.
2. Budget requested from Breakthrough T1D and the **Company’s matching funds** for project-specific resourcing during the proposed project period
3. **Governance by a Joint Research Advisory Committee** and reporting
4. Milestones and milestone-based Payments
5. **Commercialization and Future Revenue Share (Royalties):** Breakthrough T1D will receive a modest return on investment (ROI), based on the Company’s successful commercialization of product(s) derived from the funded research program, and/or other inflection point(s) as mutually agreed in the contract.
6. Intellectual Property (IP) Rights: Company will own funded research discoveries, IP, and product rights.
7. Continuation of **Commercially Reasonable Efforts (CRE)** during and after Breakthrough T1D funding; terms in the event of interruption of CRE
 - If the Company decides to abandon further development and commercialization activities, Breakthrough T1D will expect access to IP developed during the funded research program, with the right to sublicense to another entity committed to the necessary development toward commercialization.
8. Indemnification and Insurance
9. Publications and Presentations
10. Term and Termination
11. Other standard terms and conditions, to be set forth in the definitive agreement



Active Projects - IDDP Portfolio (March 2026)

Cell Therapy



Disease-Modifying Therapies



Improving Lives

(Drugs, Devices, & Complications)



Questions?

- More information can be found in the <https://www.breakthrough1d.org/granthandbook/>.
- Please e-mail preawardsupport@breakthroughT1D.org if you have questions.
- Companies interested in the T1D Fund, Breakthrough T1D's mission-driven venture philanthropy team, may email t1dfund@breakthroughT1D.org.



Breakthrough T1D™

Formerly JDRF